TABLE 2.
Efficacy of human VEEV-specific TcPAb in protection against standard-dose aerosol challengec
| TcPAb | Route | Timinga | % survival | AST (days) ± SDb |
|---|---|---|---|---|
| Negative control | Prophylactic | 0 | 7.6 ± 1.1 | |
| Therapeutic | 0 | 8.6 ± 0.5 | ||
| CLV | i.p. | Prophylactic | 20 | 6.9 ± 0.2 |
| i.p./i.n. | 60 | 7.0 ± 0.0 | ||
| i.p. | Therapeutic | 50 | 7.8 ± 0.4 | |
| i.p./i.n. | 100 | NA | ||
| pDNA694 | i.p. | Prophylactic | 80* | 9.3 ± 1.3# |
| i.p./i.n. | 80 | 8.0 ± 0.0 | ||
| i.p. | Therapeutic | 90 | 8.5 ± 0.0 | |
| i.p./i.n. | 90 | 8.0 ± 0.0 | ||
| V3000 nt3A AMT | i.p. | Prophylactic | 90* | 9.0 ± 0.0# |
| i.p./i.n. | 100 | NA | ||
| i.p. | Therapeutic | 80 | 7.8 ± 0.3 | |
| i.p./i.n. | 70 | 8.3 ± 0.8 |
a
Prophylactic treatment 12 h before challenge; therapeutic treatment at 12 h postchallenge.
b
NA, not applicable.
c
*, P < 0.05 by a chi-square test comparing CLV with pDNA694 and V3000 nt3A AMT; #, P < 0.05 by a Mantel-Cox log rank test comparing CLV with pDNA694 and V3000 nt3A AMT.